Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Compass Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 34 | 34 | 0 |
| Shares | 62.4M | 61.9M | −482.7K (−0.8%) |
| Value | $85.4M | $163.9M | +$78.6M (+92.1%) |
New holders (6)
Institutions that held Compass Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock Inc. | 163,426 | $433.0K | 0.00% |
| New Capital Management LP | 24,243 | $69.0K | 0.04% |
| Marshall Wace, LLP | 23,727 | $63.0K | 0.00% |
| Flagship Harbor Advisors, LLC | 14,000 | $37.0K | 0.00% |
| Citigroup Inc | 1,370 | $4.00K | 0.00% |
| Advisor Group Holdings, Inc. | 100 | $0 | 0.00% |
Sold out (6)
Institutions that held Compass Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Farallon Capital Management, L.L.C. | 582,750 | $798.0K |
| Ra Capital Management, L.P. | 532,958 | $730.0K |
| Alphabet Inc. | 192,794 | $264.0K |
| Ikarian Capital, LLC | 74,171 | $100.0K |
| Qube Research & Technologies Ltd | 52,842 | $72.0K |
| Bank of America Corp | 6 | $0 |